In June 2010, The Medicines Control Council (MCC) announced the intention to implement the South African Common Technical Document (ZA CTD) format which will replace the current MRF1 and any applications still in MBR1 format.
From June 2011, submissions in ZA CTD format are mandatory (excluding veterinary medicines).
Freyr is currently working with many Global Pharmaceutical and Consumer Health Care companies in supporting them in planning and executing the CTD conversion requirement for the existing and new product registrations in South Africa enabling them to meet the MCC mandate. For some of these global companies CTD conversion is a time consuming and a huge responsibility that needs careful planning and execution given their growing product portfolio in the African market.
Good Manufacturing Practice is that part of Quality Assurance which ensures that products are consistently produced and controlled to the quality standards.
Regular periodic or rolling quality reviews of all registered medicinal products, including export only products are conducted.
The Manufacturer and Holder of Certificate of Registration, where different, should evaluate the results of the review and an assessment should be made of whether corrective and preventative action or any revalidation should be undertaken.
Medicines Control Council’s (MCC) general policy is that the standard to be used to assess compliance with current Good Manufacturing Practice (cGMP), is the South African Guide to Good Manufacturing Practice (SA guide to GMP).
Under Section 22C of the Act, all South African manufacturers should be licensed
The Act requires that overseas manufacturers of medicine supplied to South Africa should comply with the same or equivalent manufacturing standards as expected of South African manufacturers
When acceptable evidence of GMP compliance is not available, overseas manufacturers are inspected by the GMP Inspectorate before registration of the medicine is approved
Medicines Registration
Medicines to be used in South Africa for both public and private sectors shall be duly registered with the national regulatory authority, the Medicines Control Council’s (MCC) in accordance with the provisions and requirements of the Medicines and Related Substances Control Act No. 101 of 1965 and the Regulations and Guidelines published in terms thereof.
A written notification from the Minister to the effect that the medicine is considered essential to national health; an expert report (which is not more than 2 (two) years old; a package insert (where the product has been approved) and a summary basis for the registration (SBRA) should be submitted with application.
The Registrar shall notify the applicant within 30 days of the date of receipt of the application and the Council shall, within 9 months make a decision with regard to the application.
The abbreviated medicine review process is based mainly on the expert reports of the pharmaco toxicological and clinical data.
Applications for Abbreviated Medicine Review Process (AMRP) can only be accepted if the product has been approved by the said authorities within the last three years of the license in the licensing country.
Regulatory Operations
Submissions Publishing
In June 2010, The Medicines Control Council (MCC) announced the intention to implement the South African common technical document (ZA CTD) format which will replace the current MRF1 and any applications still in MBR1 format. From June 2011, submissions in ZA CTD format are mandatory (excluding veterinary medicines).
With the need for converting old format submissions to CTD format comes the opportunity for Market Authorization Holders (MAH) to plan and be ready for electronic submissions. Freyr can compile submissions in eCTD format and print in paper format as required by the current MCC requirement. This allows the MAHs to be prepared for future eCTD requirements from MCC and enables efficient electronic submission dossier management.
Registrations and Submissions Information Management
Module 1 (Administrative 1.10 Foreign Regulatory Status) requirement from Medicines Control Council’s (MCC) requires the applicant to provide a list of countries in which an application for the same product is being applied for in South Africa has been submitted, dates of submission (if available). This should detail approvals (with indications). Applicants must declare whether a marketing application for the medicine has been rejected in the countries listed under 1.10.1 prior to submission of the application in South Africa. If the medicine has been rejected, repeatedly deferred or withdrawn, then the MCC must be informed and the reasons supplied.
If no application has been submitted for registration in the country of origin, include a statement to provide the reason for this decision. It should be noted that aforementioned information is required to be provided in dossier however, it does not mean that this will help to speed up the review process.
Search
Companies today require a business partner who has global expertise with dedicated resources readily available across the globe to gain new market access, to meet evolving HA compliance needs and to reduce operational cost savings for new innovations.
This business partner can either act in a do-as-directed mode, or like us, can act on our years of experience providing delivery excellence to our partners and constantly innovating to newer ways of doing business (Freyr.NEXT) and setting industry benchmarks.
We implement smarter technologies as required, and our practices can save you at least 40% of your annual Regulatory affairs spend.
Our continued mission, to ensure that our clients’ products reach the people in the farthest corners of the world, who need them, has led us to develop an unparalleled niche, but scalable on-demand model of business.
We could only reach here by leveraging our unmatched expertise in the form of a dedicated workforce providing 24/7 coverage to all our clients across the world.
We were there when the peaks in business were not covered well with the clients’ internal resources.
We were there when new mandates and guidelines needed new expertise.
We were there when the cost of mundane activities was too high and needed to be reduced.
We were there when internal resources needed to focus on strategy and the execution was left to us. Of course, we weren’t there when the workload was low and the client could handle it themselves, but even still, we were just a call away to handle any sudden peaks.
We now can showcase 700+ logos (and counting) on our jackets because we are in the business of trust.
Trust that when there is a need, Freyr’s ready to take on the load;
Trust that when there’s no expertise, Freyr is updated even before a need arises;
Trust that Freyr is continuously evolving and innovating to ensure that the journey from product development to global market penetration, and even beyond, is a smooth one.
Our partners believe in brand Freyr, because they know that certain names mean expertise, and we stand trustworthy in building the strategies that align with their core business interests.
We are proud to say that many trade names, large and small alike, backed by their R&D and our consulting and operational fine-tuning have been established through our efforts.
Operational excellence and the cost-savings, which are being provided to them, are at the heart of these establishments.
And we are proud to say that if it weren’t for us, they would be spending a lot of money locking horns with the toughest Health Authorities to please around the world.
If you wish to have us by your side, give us a call. We look forward to giving you the smooth-sailing, cost-effective world of Regulatory Partnerships all of our partners enjoy.
Freyr.
You can live without regulatory outsourcing, but not nearly as peacefully.
Freyr, with exclusive delivery hubs across the USA, UK, Canada, Germany, Mexico, UAE, Singapore, Malaysia, South Africa, Slovenia and India (Global Delivery Center); and with worldwide affiliate network across 120+ countries, offers life sciences organizations a global delivery model customized to their unique Regulatory requirements.
